There is a current shortfall of relevant in vitro models that accurately reflect the PMNs for ER+ tumors, as well as novel analysis tools to understand the molecular mechanisms driving adaptation and survival of metastatic ER+ breast cancer cells in these environments. This evidence concerns the gene ESR1 and breast carcinoma.